Serene Product Accepted into the National Cancer Institute Experimental Therapeutics Program
A human clinical trial using a new high specific activity formulation of tin-117m-DTPA has been accepted into the National Cancer Institute Experimental Therapeutics program and Serene will receive significant support, beginning with a Phase 1 trial in patients with bone…